William F. Doyle - 10 Jun 2022 Form 4 Insider Report for Minerva Neurosciences, Inc. (NERV)

Reporting relationship: Director
Issuer ticker: NERV
Reported as of: 10 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jun 2022, 19:35:30 UTC
Prior SEC filing: 09 Mar 2022
Next SEC filing: 13 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Marc Recht, Attorney-in-Fact

Key filing fact

William F. Doyle filed Form 4 for Minerva Neurosciences, Inc. (NERV) on 28 Jun 2022.

Key facts

This page summarizes William F. Doyle's Form 4 filing for Minerva Neurosciences, Inc. (NERV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Jun 2022, 19:35.

Change

Previous filing in this sequence was filed on 09 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NERV transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +2,500
Change %
Price: $0.000000
Shares after: 2,500
Date: 10 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500
Exercise price: $3.32
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This option is granted to non-employee directors in accordance with the Issuer's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 2,500 shares of common stock per year.

Footnote F2

On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split.

Footnote F3

The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 10, 2022 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.